Cargando…

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks

It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Speer, Claudius, Schaier, Matthias, Nusshag, Christian, Töllner, Maximilian, Buylaert, Mirabel, Kälble, Florian, Reichel, Paula, Grenz, Julia, Süsal, Caner, Zeier, Martin, Schnitzler, Paul, Morath, Christian, Klein, Katrin, Benning, Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539130/
https://www.ncbi.nlm.nih.gov/pubmed/34696238
http://dx.doi.org/10.3390/vaccines9101130
_version_ 1784588672360775680
author Speer, Claudius
Schaier, Matthias
Nusshag, Christian
Töllner, Maximilian
Buylaert, Mirabel
Kälble, Florian
Reichel, Paula
Grenz, Julia
Süsal, Caner
Zeier, Martin
Schnitzler, Paul
Morath, Christian
Klein, Katrin
Benning, Louise
author_facet Speer, Claudius
Schaier, Matthias
Nusshag, Christian
Töllner, Maximilian
Buylaert, Mirabel
Kälble, Florian
Reichel, Paula
Grenz, Julia
Süsal, Caner
Zeier, Martin
Schnitzler, Paul
Morath, Christian
Klein, Katrin
Benning, Louise
author_sort Speer, Claudius
collection PubMed
description It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed.
format Online
Article
Text
id pubmed-8539130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85391302021-10-24 Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks Speer, Claudius Schaier, Matthias Nusshag, Christian Töllner, Maximilian Buylaert, Mirabel Kälble, Florian Reichel, Paula Grenz, Julia Süsal, Caner Zeier, Martin Schnitzler, Paul Morath, Christian Klein, Katrin Benning, Louise Vaccines (Basel) Article It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed. MDPI 2021-10-04 /pmc/articles/PMC8539130/ /pubmed/34696238 http://dx.doi.org/10.3390/vaccines9101130 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Speer, Claudius
Schaier, Matthias
Nusshag, Christian
Töllner, Maximilian
Buylaert, Mirabel
Kälble, Florian
Reichel, Paula
Grenz, Julia
Süsal, Caner
Zeier, Martin
Schnitzler, Paul
Morath, Christian
Klein, Katrin
Benning, Louise
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
title Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
title_full Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
title_fullStr Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
title_full_unstemmed Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
title_short Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
title_sort longitudinal humoral responses after covid-19 vaccination in peritoneal and hemodialysis patients over twelve weeks
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539130/
https://www.ncbi.nlm.nih.gov/pubmed/34696238
http://dx.doi.org/10.3390/vaccines9101130
work_keys_str_mv AT speerclaudius longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT schaiermatthias longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT nusshagchristian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT tollnermaximilian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT buylaertmirabel longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT kalbleflorian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT reichelpaula longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT grenzjulia longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT susalcaner longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT zeiermartin longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT schnitzlerpaul longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT morathchristian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT kleinkatrin longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks
AT benninglouise longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks